Table 3. Characteristics for patients with any tumor regression or SD≥6 months (n=17).

Case #	Histology	Best Response %	Months on study	Smoker	EGFR	PIK3CA	p53	Prior EGFR Tx	Prior bevacizumab	Brain metastases	Dose Level	Rash Grade >3
PR
37	Adenocarcinoma	−59	10	Y	ND	ND	ND	N	N	Y	3	N
197	Mod. diff. adeno.	−55	14	N	L858R G873E	E542K	ND	Erlotinib (13 months)	Y	Y	8	N
200	Poorly-mod. diff. adeno.	−48♦	4	Y	NEG	NEG	ND	N	Y	Y	8	Y
226	Adenocarcinoma	−34♦	6	N	ND	ND	ND	Erlotinib (10 months)	N	N	8	N
SD≥6 Months
153	Poorly diff. adeno. with mucin	−24	10	N	NEG	NEG	ND	N	N	N	8	Y
39	SCC	−22	25	Y	NEG	NEG	R196*	N	N	N	3	N
90	Mucinous adeno	−16	9	N	NEG	NEG	ND	Erlotinib (5 months)	N	N	6	N
45	Adenocarcinoma	−10	7	Y	ND	ND	ND	N	Y	Y	4	N
146	Adenocarcinoma	5	6	Y	NEG	NEG	ND	Erlotinib (2 months)	Y	Y	8	N
169	Adenocarcinoma	7	12	Y	ND	ND	ND	N	Y	Y	8	N
28	Adenocarcinoma	8	6	Y	ND	ND	ND	N	N	N	2	N
SD<6 Months and tumor decrease 0-29%
228	Adenocarcinoma	−28	4	Y	NEG	E545K	ND	N	N	N	8	N
148	Adenocarcinoma	−20	2	N	Exon 20 insertion	ND	ND	N	Y	N	8	Y
207	Adenocarcinoma	−15	3	Y	NEG	NEG	ND	N	N	N	8	N
89	Poorly diff. adeno.	−13	4	Y	NEG	ND	ND	N	N	N	6	N
181	Adenocarcinoma	−11	4	Y	Exon 19 deletion	ND	ND	Erlotinib (12 months)	Y	N	8	N
40	Adenocarcinoma	−5	2	Y	ND	ND	ND	N	N	Y	3	N

Abbreviations: adeno, adenocarcinoma; diff, differentiated; mod, moderately; ND, not done; NEG, negative; PR, partial response; SCC, squamous cell carcinoma; SD; stable disease; Tx, treatment

^♦Indicates an unconfirmed PR.